FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi
Johnson & Johnson said the U.S. Food and Drug Administration approved its once-daily psoriasis pill, the first oral option to rival best-selling shots.
TL;DR
- The FDA approved J&J's once-daily pill, Icotyde, for moderate to severe plaque psoriasis.
- Icotyde is the first oral option to rival best-selling injectable psoriasis treatments like J&J's Tremfya and AbbVie's Skyrizi.
- The drug targets the IL-23 receptor, offering an oral alternative to advanced and expensive injectable therapies.
- J&J estimates about 8 million people in the U.S. have plaque psoriasis, with many avoiding shots due to needle fear.
- J&J anticipates peak annual sales of Icotyde to exceed $5 billion and is testing it for psoriatic arthritis, ulcerative colitis, and Crohn's disease.
- Shares of J&J saw a slight decline, while AbbVie's shares fell more significantly on the news.